Matinas BioPharma (MTNB) Announces Collaboration with NIAID to Evaluate Oral Formulations of Gilead's (GILD) Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. HOOD
8. DFTX
9. MU
10. IBM

Go back to Matinas BioPharma (MTNB) Announces Collaboration with NIAID to Evaluate Oral Formulations of Gilead's (GILD) Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology
Gilead Sciences (NASDAQ: GILD) Delayed: 124.87 +1.11 (0.90%)
Previous Close $123.76    52 Week High $108.63 
Open $124.30    52 Week Low $71.39 
Day High $125.17    P/E 68.99 
Day Low $123.00    EPS $1.81 
Volume 8,126,292       

(NYSE: MTNB) Delayed: 0.63 +0.03 (5.00%)
Previous Close $0.60    52 Week High $2.01 
Open $0.60    52 Week Low $0.41 
Day High $0.67    P/E N/A 
Day Low $0.60    EPS $0.00 
Volume 27,353